Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor currently approved in the United Kingdom for the treatment of moderate‐to‐severe atopic dermatitis (AD). As patients with AD may use medications to manage comorbidities, abrocitinib could be used concomitantly with hepatic and/or renal transport...

Descripción completa

Detalles Bibliográficos
Autores principales: Vourvahis, Manoli, Byon, Wonkyung, Chang, Cheng, Le, Vu, Diehl, Annette, Graham, Daniela, Tripathy, Sakambari, Raha, Nancy, Luo, Lina, Mathialagan, Sumathy, Dowty, Martin, Rodrigues, A. David, Malhotra, Bimal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540496/
https://www.ncbi.nlm.nih.gov/pubmed/35344588
http://dx.doi.org/10.1002/cpt.2594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540496/
https://www.ncbi.nlm.nih.gov/pubmed/35344588
http://dx.doi.org/10.1002/cpt.2594

Ejemplares similares